Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ANTX stock hub

AN2 Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ANTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

160.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ANTX

In the news

Latest news · ANTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-52.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-35.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ANTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

169

Groups with data

Currency

USD

Showing 169 of 169 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001880438
Company name	AN2 Therapeutics, Inc.
Country	United States
Country code	US
Cusip	037326105
Employees	21
Employees Change	-1%
Employees Change Percent	-4.55
Enterprise value	$102.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2022-03-25
Isin	US0373261058
Last refreshed	2026-05-10
Market cap	$160.5M
Market cap category	Micro-Cap
Price	$4.46
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	ANTX
Website	https://www.an2therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-21.91%
P/B ratio	2.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-35.2M
Net Income Growth Years	2%
Profit Per Employee	$-1.7M
ROA	-30.93
Roa5y	-33.36
ROCE	-71.59
ROE	-52.14
Roe5y	-55.88
ROIC	-35.31

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	259.99%
Cagr3y	-7.85%
EPS Growth Years	4
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$62M
Cash	$58M
Current Assets	$59.9M
Current Liabilities	$8.7M
Equity	$53.1M
Liabilities	$8.9M
Long Term Assets	$2M
Long Term Liabilities	$170,000
Net Cash	$58M
Net Cash By Market Cap	$36.13
Net Cash Growth	-30.64%
Net Debt Equity	$-1.09
Tangible Book Value	$53.1M
Tangible Book Value Per Share	$1.94
WACC	-1

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.87
Net Working Capital	$-6.8M
Quick ratio	6.75
Working Capital	$51.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.3%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	259.68%
200-day SMA	1.81
3Y total return	-21.75%
50-day SMA	3.77
50-day SMA vs 200-day SMA	50over200
All Time High	23.58
All Time High Change	-81.09%
All Time High Date	2022-05-16
All Time Low	0.87
All Time Low Change	412.64%
All Time Low Date	2024-08-09
ATR	0.38
Beta	-0.96
Beta1y	-2.28
Beta2y	-0.12
Ch YTD	291.2
High	4.83
High52	6.91
High52 Date	2026-03-09
High52ch	-35.46%
Low	4.46
Low52	1
Low52 Date	2026-02-19
Low52ch	346%
Ma50ch	18.33%
Premarket Change Percent	-4.35
Premarket Price	$4.4
Premarket Volume	10,086
Price vs 200-day SMA	146.41%
RSI	58.95
RSI Monthly	53.72
RSI Weekly	68.38
Sharpe ratio	1.45x
Sortino ratio	4.7
Total Return	-1.3%
Tr YTD	291.2
Tr1m	35.15%
Tr1w	-4.7%
Tr3m	309.17%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Count Top	1
Analyst Price Target Top	$2
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.23
Operating Income	$-38.1M
Price target	$2
Price Target Change	$-55.16
Price Target Change Top	$-55.16

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17,008,858%
Float Percent	47.25%
Shares Insiders	6.03%
Shares Institutions	22.67%
Shares Out	35,995,545
Shares Qo Q	0.27%
Shares Yo Y	1.3%
Short Float	3.73%
Short Ratio	1.52
Short Shares	1.76

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	313,660.95x
Bv Per Share	1.94
Ch1m	35.15
Ch1w	-4.7
Ch1y	259.7
Ch3m	309.2
Ch3y	-21.75
Ch6m	291.2
Change	-3.04%
Change From Open	-2.83
Close	4.6
Days Gap	-0.22
Dollar Volume	1,079,101.5
Earnings Date	2026-05-13
Earnings Time	amc
EBIT	$-38.1M
EPS	$-1.16
F Score	1
Financing CF	113,000
Fiscal Year End	December
Founded	2,017
Investing CF	28,311,000
Ipr	-70.27
Iprfo	-73.53
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-17
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-17
Ma150	2.02
Ma150ch	120.36%
Ma20	4.14
Ma20ch	7.81%
Net CF	-1,410,000
Next Earnings Date	2026-05-22
Open	4.59
Optionable	No
Position In Range	0
Post Close	4.46
Postmarket Change Percent	-0.22
Postmarket Price	$4.45
Pre Close	4.6
Price Date	2026-05-08
Ptbv Ratio	3.03
Relative Volume	0.77x
Share Based Comp	6,246,000
Tr6m	291.23%
Us State	California
Volume	241,951

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ANTX pay a dividend?

Capital-return profile for this ticker.

Performance

ANTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ANTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.7%

Float: +47.3% of shares outstanding

Insider ownership

+6.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ANTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

59.0

Neutral momentum band

Price vs 200-day MA

+146.4%

50/200-day relationship not available

Beta (5Y)

-0.96

Less volatile than the market

Sharpe ratio

1.45

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ANTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ANTX stock rating?

AN2 Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ANTX analysis?

The full report lives at /stocks/ANTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ANTX?

The latest report frames ANTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ANTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.